Early Detection in Alzheimer's Disease

Early Detection in Alzheimer's Disease

Biological and Technological Advances

1st Edition - December 1, 2022

Write a review

  • Editor: Dennis Chan
  • Paperback ISBN: 9780128222409

Purchase options

Purchase options
Available for Pre-Order
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Early Detection of Alzheimer’s Disease: Biological and Technological Advances aims to introduce to a wide audience the high global priority problem of detecting AD prior to dementia onset. According to the Alzheimer’s Association, 5.8 million Americans are living with Alzheimer’s and care costs will cost the nation approximately $290 billion (2019 Alzheimer’s Disease Facts and Figures). With the failure of recent AD drug trials, many hypothesize that by the time symptoms appear, it is too late to be treated. Early detection can offer benefits such as more choice of medications, ability to participate in clinical trials, more time for family and for care planning. This book outlines potential solutions to the above problem using opportunities arising from the technology revolution, advances in neuroscience, and molecular biology. Most importantly, it discusses a paradigm shift from a reactive to a proactive diagnostic approach, aiming to detect disease before occurrence of symptoms. Topics covered include the use of sensing technologies (e.g. smartphones, smartwatches, Internet of Things) to detect early disease-related changes, the application of data science (machine learning/AI) to extract otherwise invisible disease features from these datasets and the potential to personalize diagnosis based on tracking changes in individual behaviours. Advances in blood-based biomarkers, brain imaging, and the potential for early diagnosis to aid interventions (lifestyle, dietary, pharmacological) to delay future development of dementia are also discussed.

Key Features

  • Outlines the importance of early diagnosis of Alzheimer’s Disease
  • Helps readers understand the limitations of current clinical approaches and the need for a paradigmatic shift in diagnostic practice
  • Discusses the potential role of technology in clinical practice using machine learning and artificial intelligence and the potential to personize diagnosis and treatment

Readership

Neuroscientists, neurologists, psychiatrists and nurse practitioners focused on AD

Table of Contents

  • 1. Foreword

    2. Introduction
    Opportunities and challenges provided by the tech revolution
    The need for futureproofing and the importance of mitigating against the risk of obsolescence

    3. Early Alzheimer’s disease
    Pathology
    The syndrome of mild cognitive impairment
    Management

    4. The need for early diagnosis
    Clinical, societal and health economic drivers
    The aging population
    Global inequalities in access to diagnostics
    Scientific drivers
    The need to integrate with basic neuroscience
    Need for functionally relevant outcome measures

    5. An overview of current diagnostic strategies
    Neuroimaging
    Cognitive testing
    Clinical evaluation

    6. Novel approaches to diagnosis
    Opportunities arising from the tech revolution
    App-based testing
    Machine learning/AI
    Big data
    Personalised diagnostics
    Advances in imaging
    Advances in biomarkers, incl blood-based methods
    Advances in cognitive testing

    7. Challenges for the new approach
    Ethical issues about early diagnosis in the absence of a cure
    Privacy

    8. An eye to the future
    Beyond diagnosis: how to use such approaches for intervention
    Clinical trials
    the emerging landscape of disease-modifying drugs
    novel trial outcome measures
    Non-pharmacological interventions
    Next generation approaches

Product details

  • No. of pages: 300
  • Language: English
  • Copyright: © Academic Press 2023
  • Published: December 1, 2022
  • Imprint: Academic Press
  • Paperback ISBN: 9780128222409

About the Editor

Dennis Chan

Dr. Chan, PhD MD FRCP is an academic neurologist with a special interest in the diagnosis of Alzheimer’s disease prior to the onset of dementia. He holds dual research doctorates in basic and clinical neuroscience. His NHS practice is based at Addenbrooke’s Hospital, Cambridge, where he undertakes clinics in general neurology, dementia and mild cognitive impairment. His research focuses on identifying alterations in the function of the entorhinal cortex (EC) and hippocampus in early Alzheimer's disease (AD), with the ultimate aim of diagnosing AD prior to symptom onset.

Affiliations and Expertise

Consultant Neurologist, Cambridge and Peterborough NHS Foundation Trust Hononary Associate Professor, University College London, London, UK

Ratings and Reviews

Write a review

There are currently no reviews for "Early Detection in Alzheimer's Disease"